Inhaled aztreonam for chronic burkholderia infection in cystic fibrosis: A placebo-controlled trial

Journal of Cystic Fibrosis

Volumn 13, Issue 3, 2014, Pages 296-305

  Tullis, D Elizabeth ^a   Burns, Jane L ^b   Retsch Bogart, George Z ^c   Bresnik, Mark ^d   Henig, Noreen R ^d   Lewis, Sandra A ^e   LiPuma, John J ^f  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF WASHINGTON   (United States)

^c UNIVERSITY OF NORTH CAROLINA   (United States)

^d GILEAD SCIENCES   (United States)

^e Gilead Sciences   (United States)

^f UNIVERSITY OF MICHIGAN   (United States)

Author keywords

Antipseudomonal; Cepacia complex; Inhaled antibiotics; Pseudomonas aeruginosa; Respiratory exacerbations

Indexed keywords

AZTREONAM; AZTREONAM LYSINE; PLACEBO; ANTIINFECTIVE AGENT;

ADOLESCENT; ADULT; ARTICLE; BURKHOLDERIA INFECTION; CHILD; CHILL; CONTROLLED STUDY; CYSTIC FIBROSIS; DOUBLE BLIND PROCEDURE; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; FORCED EXPIRATORY VOLUME; HOSPITALIZATION; HUMAN; LUNG FIBROSIS; MAJOR CLINICAL STUDY; MALE; MEDICAL CARE; MULTICENTER STUDY; NEBULIZER; PHASE 3 CLINICAL TRIAL; PRESCHOOL CHILD; RANDOMIZED CONTROLLED TRIAL; SCHOOL CHILD; VIRUS INFECTION; WHEEZING; BURKHOLDERIA INFECTIONS; CHRONIC DISEASE; CLINICAL TRIAL; INHALATIONAL DRUG ADMINISTRATION; MICROBIOLOGY; TREATMENT OUTCOME; YOUNG ADULT;

ADMINISTRATION, INHALATION; ADOLESCENT; ADULT; ANTI-BACTERIAL AGENTS; AZTREONAM; BURKHOLDERIA INFECTIONS; CHILD; CHRONIC DISEASE; CYSTIC FIBROSIS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; PLACEBOS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84897115508     PISSN: 15691993     EISSN: 18735010     Source Type: Journal    
DOI: 10.1016/j.jcf.2013.08.011     Document Type: Article

References (32)

1. LiPuma J.J. The changing microbial epidemiology in cystic fibrosis. Clin Microbiol Rev 2010, 23:299-323.
2. Cystic Fibrosis Foundation Cystic Fibrosis Foundation Patient Registry: Annual Data Report Available at:. http://www.cff.org/UploadedFiles/LivingWithCF/CareCenterNetwork/PatientRegistry/2010-Patient-Registry-Report.pdf.
3. Cystic Fibrosis Canada Canadian cystic fibrosis patient data registry report Available at:. http://www.cysticfibrosis.ca/assets/files/pdf/CPDR_ReportE.pdf.
4. Courtney J.M., Dunbar K.E.A., McDowell A., Moore J.E., Warke T.J., Stevenson M., et al. Clinical outcome of Burkholderia cepacia complex infection in cystic fibrosis adults. J Cyst Fibros 2004, 3:93-98.
5. Lynch J.P. Burkholderia cepacia complex: impact on the cystic fibrosis lung lesion. Semin Respir Crit Care Med 2009, 30:596-610.
6. Horsley A., Jones A.M. Antibiotic treatment for Burkholderia cepacia complex in people with cystic fibrosis experiencing a pulmonary exacerbation. Cochrane Database Syst Rev 2012, 10:CD009529. 10.1002/14651858.CD009529.pub2.
7. Foster J., Burns J.L. Aztreonam susceptibility of pathogens isolated from CF patients [Abstract 331]. Pediatr Pulmonol 2003, 25:298. (Suppl.).
8. Traczewski M.M., Brown S.D. In vitro activity of doripenem against Pseudomonas aeruginosa and Burkholderia cepacia isolates from both cystic fibrosis and non-cystic fibrosis patients. Antimicrob Agents Chemother 2006, 50:819-821.
9. Bosso J.A., Saxon B.A., Matsen J.M. Comparative activity of cefepime, alone and in combination, against clinical isolates of Pseudomonas aeruginosa and Pseudomonas cepacia from cystic fibrosis patients. Antimicrob Agents Chemother 1991, 35:783-784.
10. Tullis E., Burns J.L., Retsch-Bogart G., Bresnik M., Henig N.R., Lewis S., et al. Aztreonam for inhalation solution (AZLI) in cystic fibrosis (CF) patients with chronic Burkholderia species (BURK) infection: initial results from a randomized, placebo-controlled trial [abstract 234]. Pediatr Pulmonol 2011, 46(Suppl. 34):296.
11. Tullis E., LiPuma J.J., Retsch-Bogart G., Bresnik M., Henig N.R., McKevitt M., et al. Effects of continuous aztreonam for inhalation solution (AZLI) use on pathogens and antibiotic susceptibility in cystic fibrosis (CF) patients with chronic Burkholderia species infection [abstract 257]. Pediatr Pulmonol 2011, 46(Suppl. 34):305.
12. Tullis E., Burns J.L., Retsch-Bogart, Bresnik M., McKevitt M., Lewis S., et al. Aztreonam for inhalation solution (AZLI) in cystic fibrosis (CF) patients with chronic Burkholderia species (BURK) infection: a randomized, placebo controlled trial [Abstract B1] IBCWG 2012 Abstract Book: 5-6. Available at:. http://go.to/cepacia.
13. Tullis E., Burns J.L., Retsch-Bogart, Bresnik M., Henig N.R., Lewis S., et al. Aztreonam for inhalation solution (AZLI) in cystic fibrosis (CF) patients with chronic Burkholderia species (BURK) infection: final results from a randomized, placebo-controlled trial [abstract]. J Cyst Fibros 2012, 11(Suppl. 1):S11.
14. Hankinson J.L., Odencrantz J.R., Fedan K.B. Spirometric reference values from a sample of the general U.S. population. Am J Respir Crit Care Med 1999, 159:179-187.
15. Wang X., Dockery D.W., Wypju D., Fay M.E., Ferris B.G. Pulmonary function between 6 and 18years of age. Pediatr Pulmonol 1993, 15:75-78.
16. Quittner A.L., Buu A., Messer M.A., Modi A.C., Watrous M. Development and validation of The Cystic Fibrosis Questionnaire in the United States: a health-related quality-of-life measure for cystic fibrosis. Chest 2005, 128:2347-2354.
17. Emerson J., McNamara S., Buccat A.M., Worrell K., Burns J.L. Changes in cystic fibrosis sputum microbiology in the United States between 1995 and 2008. Pediatr Pulmonol 2010, 45:363-370.
18. Burns J.L., Emerson J., Stapp J.R., Yim D.L., Krzewinski J., Louden L., et al. Microbiology of sputum from patients at cystic fibrosis centers in the United States. Clin Infect Dis 1998, 27:158-163.
19. LiPuma J.J., Dulaney B.J., McMenamin J.D., Whitby P.W., Stull T.L., Coenye T., et al. Development of rRNA-based PCR assays for identification of Burkholderia cepacia complex isolates recovered from cystic fibrosis patients. J Clin Microbiol 1999, 37:3167-3170.
20. Whitby P.W., Pope L.C., Carter K.B., LiPuma J.J., Stull T.L. Species specific PCR as a tool for the identification of Burkholderia gladioli. J Clin Microbiol 2000, 38:282-285.
21. Coenye T., Vandamme P., Govan J.R.W., LiPuma J.J. Taxonomy and identification of the Burkholderia cepacia complex. J Clin Microbiol 2001, 39:3427-3436.
22. Vermis K., Coenye T., Mahenthiralingam E., Nelis H.J., Vandamme P. Evaluation of species specific recA-based PCR tests for genomovar level identification within the Burkholderia cepacia complex. J Med Microbiol 2002, 51:937-940.
23. Spilker T., Baldwin A., Bumford A., Dowson C.G., Mahenthiralingam E., LiPuma J.J. Expanded multilocus sequence typing for Burkholderia species. J Clin Microbiol 2009, 47:2607-2610.
24. Dmitrienko A., Offen W.W., Westfall P.H. Gatekeeping strategies for clinical trials that do not require all primary effects to be significant. Stat Med 2003, 22:2387-2400.
25. Retsch-Bogart G.Z., Quittner A.L., Gibson R.L., Oermann C.M., McCoy K.S., Montgomery A.B., et al. Efficacy and safety of inhaled aztreonam lysine for airway Pseudomonas in cystic fibrosis. Chest 2009, 135:1223-1232.
26. Reik R., Spilker T., Lipuma J.J. Distribution of Burkholderia cepacia complex species among isolates recovered from persons with or without cystic fibrosis. J Clin Microbiol 2005, 43:2926-2928.
27. Konstan M.W., Wagener J.S., VanDevanter D.R. Characterizing aggressiveness and predicting future progression of CF lung disease. J Cyst Fibros 2009, (Suppl. 1):S15-S19.
28. Assael B.M., Pressler T., Bilton D., Fayon M., Fischer R., Chiron R., et al. Inhaled aztreonam lysine vs. inhaled tobramycin in cystic fibrosis: a comparative efficacy trial. J Cyst Fibros 2013, 130-140.
29. Oermann C.M., Retsch-Bogart G.Z., Quittner A.L., Gibson R.L., McCoy K.S., Montgomery A.B., et al. An 18-month study of the safety and efficacy of repeated courses of inhaled aztreonam lysine in cystic fibrosis. Pediatr Pulmonol 2010, 45:1121-1134.
30. McCoy K.S., Quittner A.L., Oermann C.M., Gibson R.L., Retsch-Bogart G.Z., Montgomery A.B. Inhaled aztreonam lysine for chronic airway Pseudomonas aeruginosa in cystic fibrosis. Am J Respir Crit Care Med 2008, 178:921-928.
31. Wainwright C.E., Quittner A.L., Geller D.E., Nakamura C., Wooldridge J.L., Gibson R.L., et al. Aztreonam for inhalation solution (AZLI) in patients with cystic fibrosis, mild lung impairment, and P. aeruginosa. J Cyst Fibros 2011, 10:234-242.
32. Cystic Fibrosis Foundation Patient registry. Annual Data Report to the Center Directors 2011.